Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:03:28.400Z.
Calculation as of: 2026-10-06T18:03:28.400Z.
Quote observation: 2026-10-06T18:00:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$990.42M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$984.44M
EV/Sales Ratio
2.40x
TTM Avg
16.24x
3Y Avg
25.95x
5Y Avg
23.23x
Market Cap
$982.42M
EV/Sales Ratio
2.47x
TTM Avg
4.19x
3Y Avg
12.20x
5Y Avg
19.04x
Market Cap
$982.34M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.18M
EV/Sales Ratio
1.58x
TTM Avg
1.77x
3Y Avg
2.17x
5Y Avg
3.33x
Market Cap
$1.01B
EV/Sales Ratio
N/A
TTM Avg
38.08x
3Y Avg
38.08x
5Y Avg
38.08x
Market Cap
$966.09M
EV/Sales Ratio
88.95x
TTM Avg
120.79x
3Y Avg
120.79x
5Y Avg
120.79x
Market Cap
$1.02B
EV/Sales Ratio
1.84x
TTM Avg
1.91x
3Y Avg
1.91x
5Y Avg
1.91x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $990.42M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $984.44M | 2.40x | 16.24x | 25.95x | 23.23x |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $982.42M | 2.47x | 4.19x | 12.20x | 19.04x |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.34M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $997.50M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.18M | 1.58x | 1.77x | 2.17x | 3.33x |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | 38.08x | 38.08x | 38.08x |
| Aktis Oncology, Inc. (AKTS)vs › | $966.09M | 88.95x | 120.79x | 120.79x | 120.79x |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.84x | 1.91x | 1.91x | 1.91x |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | 31.97x | 409.08x | 413.14x | 302.30x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
